Tempus Announces Real World Data Collaboration with BioNTech

Rhea-AI Summary

Tempus AI (NASDAQ: TEM) has announced a multi-year collaboration with BioNTech SE (Nasdaq: BNTX) to enhance BioNTech's next-generation oncology pipeline. The partnership leverages Tempus' large multimodal datasets and computational biology expertise to support BioNTech's research and development efforts in oncology.

Tempus will provide analytical support and access to its real-world multimodal database to help BioNTech generate novel insights into biological mechanisms. This collaboration aims to advance the discovery of new therapies and enhance the development of BioNTech's clinical oncology pipeline. The partnership combines Tempus' real-world data and computational technology with BioNTech's AI capabilities and multi-platform discovery engine to potentially bring innovative therapies to cancer patients.

Positive

• Multi-year collaboration with BioNTech, a global next-generation immunotherapy company
• Leveraging Tempus' large multimodal datasets for oncology research
• Potential to enhance BioNTech's next-generation oncology pipeline
• Access to Tempus' real-world multimodal database for novel insights

Negative

• None.

Insights

Medical Research Analyst

This collaboration between Tempus and BioNTech represents a significant step in leveraging real-world data for oncology drug development. Tempus' extensive multimodal datasets, combined with BioNTech's innovative approach to immunotherapy, could potentially accelerate the discovery and development of novel cancer treatments. The partnership aims to enhance BioNTech's oncology pipeline by providing deeper insights into biological mechanisms and patient responses.

Key points to consider:

• The collaboration may lead to more targeted and effective cancer therapies
• Real-world data analysis could improve patient selection for clinical trials
• The partnership could potentially reduce drug development timelines and costs

While promising, it's important to note that the impact on actual drug approvals and market success remains to be seen. Investors should monitor future updates on specific developments resulting from this collaboration.

Tech Expert

This partnership highlights the growing importance of AI and big data in drug discovery. Tempus' expertise in computational biology and real-world data analysis, combined with BioNTech's AI capabilities and multi-platform discovery engine, creates a powerful synergy. This collaboration could potentially:

• Accelerate the identification of novel drug targets
• Optimize clinical trial designs through better patient stratification
• Enhance the understanding of complex biological pathways in cancer

The integration of large-scale multimodal datasets with advanced AI algorithms represents a cutting-edge approach in precision medicine. However, the success of this collaboration will depend on the quality of data integration and the effectiveness of the AI models developed. Investors should keep an eye on any breakthroughs or patents resulting from this partnership, as they could significantly impact both companies' market positions.

Financial Analyst

This strategic collaboration has positive implications for both Tempus and BioNTech. For Tempus, it validates the value of their real-world data and AI capabilities, potentially leading to increased demand for their services in the pharmaceutical industry. For BioNTech, it could enhance their competitive edge in the oncology space by accelerating drug discovery and development processes.

Financial considerations:

• Potential for increased revenue streams for Tempus through data licensing and analytical services
• Possible reduction in R&D costs for BioNTech through more efficient drug development processes
• Enhanced market positioning for both companies in the competitive oncology and AI-driven healthcare sectors

While the financial terms of the deal are not disclosed, this type of collaboration often involves milestone payments and royalties, which could provide long-term value for both companies. Investors should monitor future earnings reports for indications of how this partnership impacts each company's financial performance.

The strategic collaboration will leverage Tempus’ large multimodal datasets to enhance BioNTech’s next-generation oncology pipeline

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM, “Tempus”), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a multi-year collaboration with BioNTech SE (Nasdaq: BNTX, “BioNTech”), a global next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. This collaboration leverages Tempus' robust multimodal datasets in support of BioNTech’s next-generation oncology pipeline.

Under this collaboration, Tempus is providing analytical support and computational biology expertise to BioNTech across its comprehensive research and development oncology pipeline. BioNTech will work collaboratively with Tempus to leverage Tempus’ real-world multimodal database to generate novel insights into the biological mechanisms supporting the discovery of new therapies and aiming to enhance the development of BioNTech’s clinical oncology pipeline.

“We are looking forward to collaborating with BioNTech to combine our real-world multimodal data and cutting-edge computational technology to help advance their differentiated oncology pipeline,” said Ryan Fukushima, Chief Operating Officer of Tempus. “By applying Tempus' extensive real-world multimodal data to BioNTech's AI capabilities and multi-platform discovery engine, we believe we can generate a real impact by working to bring novel therapies to those cancer patients who could potentially benefit the most.”

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release including statements regarding the expected outcomes and benefits of the collaboration with BioNTech. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240904479587/en/

Erin Carron

media@tempus.com

Source: Tempus AI, Inc.

FAQ

What is the purpose of Tempus' collaboration with BioNTech?

The collaboration aims to leverage Tempus' large multimodal datasets to enhance BioNTech's next-generation oncology pipeline, supporting the discovery of new therapies and advancing clinical development.

How will Tempus (TEM) contribute to BioNTech's oncology research?

Tempus will provide analytical support, computational biology expertise, and access to its real-world multimodal database to help BioNTech generate novel insights into biological mechanisms for therapy discovery and development.

What technologies are being combined in the Tempus-BioNTech collaboration?

The collaboration combines Tempus' real-world multimodal data and computational technology with BioNTech's AI capabilities and multi-platform discovery engine to advance oncology research and development.

When was the collaboration between Tempus (TEM) and BioNTech announced?

The multi-year collaboration between Tempus and BioNTech was announced on the date of the press release, though the specific date is not provided in the given information.